Table 1.

Baseline characteristics and demographics by biomarker (n: number of patients; FISH: fluorescence in situ hybridization; H-Score: immunohistochemistry score)

	All patients (N = 1,313)	FISH+ (N = 400)	H-score ≥ 200 (N = 295)	KRAS mutant (N = 166)	p-value
Age median (range)	63 (20–86)	63 (35–84)	63 (20–83)	62 (36–82)	0.93
Sex
• Female	569 (43%)	160 (40%)	116 (39%)	84 (51%)
• Male	744 (57%)	240 (60%)	179 (61%)	82 (49%)	0.04
Race
• Caucasian	1,133 (86%)	341 (85 %)	254 (86%)	147 (89%)
• African-American	116 (9%)	36 (9%)	29 (10%)	12 (7%)
• Other/Unknown	64 (5%)	23 (6%)	12 (4%)	7 (4%)	0.58
Treated with Bevacizumab
• Yes	560 (43%)	167 (42%)	84 (28%)	80 (48%)
• No	753 (57 %)	233 (58 %)	211 (72%)	86 (52%)	0.00003
Smoking status
• Current/former smoker	1,197 (91%)	364 (91%)	267 (91%)	161 (97%)
• Never smoker		36 (9%)	28 (9%)	5 (3%)	0.02
Stage
• M1a	298 (23%)	97 (24%)	85 (29%)	41 (25%)
• M1b	1,015 (77%)	303 (76%)	210 (71%)	125 (75%)	0.37
Histology
• Adenocarcinoma	819 (62%)	250 (63%)	133 (45%)	135 (81%)
• Squamous cell	321 (24%)	111 (28%)	129 (44%)	16 (10%)
• Other	172 (13%)	39 (10%)	33 (11%)	15 (9%)
• Not reported	1 (0%)	0 (0%)	0 (0%)	0 (0%)	8 x 10−14
Performance status
• 0	485 (37%)	145 (36%)	108 ((37%)	73 (44%)
• 1	827 (63%)	255 (64%)	187 (63%)	93 (56%)
• Not reported	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0.19
FISH
Has result	976 (74%)		271 (92%)	158 (95%)
Positive	400 (41%)		142 (52%)	59 (37%)
H-score
Has result	945 (72%)	360 (90%)		154 (93%)
>200	295 (31%)	142 (39%)		34 (22%)
KRAS
Has result	627 (48%)	243 (61%)	200 (68%)
Mutation positive	166 (26%)	59 (24%)	34 (17%)